STRATA Skin Sciences Partners with Johns Hopkins Dermatology to Introduce XTRAC Laser
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy SSKN?
STRATA Skin Sciences announces that Johns Hopkins Dermatology has added the XTRAC 308 nm excimer laser to its clinical treatment offerings. The addition of XTRAC enhances Johns Hopkins' ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the department, reinforcing its commitment to evidence-based dermatologic innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SSKN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SSKN
Wall Street analysts forecast SSKN stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.190
Low
4.00
Averages
4.00
High
4.00
Current: 0.190
Low
4.00
Averages
4.00
High
4.00
No data
About SSKN
STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
STRATA Skin Sciences Files for Deregistration
- Deregistration Filing: STRATA Skin Sciences filed Form 25 with the SEC to deregister its common stock, indicating that trading on Nasdaq will be suspended as of February 19, 2026, which highlights significant financial challenges faced by the company.
- Termination of Reporting Obligations: The company expects to file Form 15 around March 2, 2026, to terminate its registration and suspend reporting obligations, effectively initiating a 'going dark' process that may impact investor confidence regarding its future.
- Market Reaction: The suspension of trading due to the deregistration filing could lead to decreased liquidity, prompting investors to closely monitor the company's financial health and potential impacts on shareholders.
- Strategic Shift: This move may represent a strategic adjustment by the company in response to current market conditions and financial pressures, reflecting significant changes in its operational model and capital structure.
See More
Pitney Bowes Q4 Earnings Beat Expectations, Shares Surge
- Earnings Surprise: Pitney Bowes reported an adjusted EPS of 45 cents for Q4, surpassing the analyst consensus of 38 cents, indicating strong profitability and boosting investor confidence.
- Sales Miss: The quarterly sales of $478 million fell short of the expected $486.68 million, highlighting some market demand challenges that could impact future revenue growth.
- Stock Surge: The company's shares jumped 7.9% to $11.05 in pre-market trading, reflecting optimistic market sentiment regarding its future prospects and potentially attracting more investor interest.
- Positive Guidance: Pitney Bowes issued FY26 adjusted EPS guidance with a midpoint above estimates, further strengthening market confidence in its long-term growth potential.
See More
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
- Significant Price Surge: ZIM Integrated Shipping shares jumped 38.1% to $30.65 in pre-market trading, indicating strong market optimism regarding its future performance, which may attract more investor interest.
- Positive Market Reaction: This notable price fluctuation reflects investor confidence in the company's potential growth and profitability, potentially leading to further increases in subsequent trading days and enhancing its market position.
- Industry-Wide Impact: The surge in ZIM's stock price could influence investor sentiment across the shipping industry, prompting fluctuations in the stock prices of other related companies and affecting overall industry performance.
- Increased Investor Attention: As the stock price rises, ZIM may attract more attention from analysts and investors, further driving its market performance and trading volume, thereby strengthening the company's competitiveness in the shipping market.
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
Fastly Reports Strong Quarterly Earnings Exceeding Expectations
- Strong Earnings Performance: Fastly reported earnings of $0.12 per share, surpassing analyst expectations of $0.06, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Significant Revenue Growth: The quarterly revenue reached $172.61 million, exceeding Wall Street's estimate of $161.36 million and up from $140.58 million in the same period last year, demonstrating the company's robust performance amid recovering market demand.
- Stock Price Surge: Fastly's shares jumped 34.8% to $12.55 in pre-market trading, reflecting a positive investor reaction to the earnings report, which may attract more investor interest in its future developments.
- Increased Market Confidence: The strong earnings report not only enhances investor confidence but may also prompt analysts to revise their ratings and price targets for the company, potentially driving further stock price increases.
See More
STRATA Showcases New Technologies at 2025 Dermatology Congress, Anticipates 12 New Clients in Mexico
- Technology Showcase: At the 2025 Ibero-Latin American Dermatology Congress, STRATA presented its XTRAC® laser and TheraclearX® acne therapy system, garnering significant interest from dermatologists and reinforcing the company's leadership in dermatological technologies.
- Market Expansion: STRATA anticipates over 12 new recurring TheraclearX® accounts in Mexico by the end of 2025, reflecting growing acceptance of non-drug treatment options among dermatologists in the region, which will drive sustainable revenue growth for the company.
- Clinical Feedback: At the congress, the first TheraClearX® user in Mexico shared her successful experience in treating mild to moderate acne, highlighting the technology's potential for significant patient improvement in a short session, which could enhance adoption rates.
- Strategic Outlook: STRATA is committed to expanding access to advanced dermatology solutions across Latin America, engaging with key opinion leaders to enhance market penetration and drive revenue growth through device-based therapies.
See More
STRATA Skin Sciences Files for Deregistration
- Deregistration Filing: STRATA Skin Sciences filed Form 25 with the SEC to deregister its common stock, indicating that trading on Nasdaq will be suspended as of February 19, 2026, which highlights significant financial challenges faced by the company.
- Termination of Reporting Obligations: The company expects to file Form 15 around March 2, 2026, to terminate its registration and suspend reporting obligations, effectively initiating a 'going dark' process that may impact investor confidence regarding its future.
- Market Reaction: The suspension of trading due to the deregistration filing could lead to decreased liquidity, prompting investors to closely monitor the company's financial health and potential impacts on shareholders.
- Strategic Shift: This move may represent a strategic adjustment by the company in response to current market conditions and financial pressures, reflecting significant changes in its operational model and capital structure.
See More
Pitney Bowes Q4 Earnings Beat Expectations, Shares Surge
- Earnings Surprise: Pitney Bowes reported an adjusted EPS of 45 cents for Q4, surpassing the analyst consensus of 38 cents, indicating strong profitability and boosting investor confidence.
- Sales Miss: The quarterly sales of $478 million fell short of the expected $486.68 million, highlighting some market demand challenges that could impact future revenue growth.
- Stock Surge: The company's shares jumped 7.9% to $11.05 in pre-market trading, reflecting optimistic market sentiment regarding its future prospects and potentially attracting more investor interest.
- Positive Guidance: Pitney Bowes issued FY26 adjusted EPS guidance with a midpoint above estimates, further strengthening market confidence in its long-term growth potential.
See More
ZIM Integrated Shipping Shares Surge 38.1% in Pre-Market Trading
- Significant Price Surge: ZIM Integrated Shipping shares jumped 38.1% to $30.65 in pre-market trading, indicating strong market optimism regarding its future performance, which may attract more investor interest.
- Positive Market Reaction: This notable price fluctuation reflects investor confidence in the company's potential growth and profitability, potentially leading to further increases in subsequent trading days and enhancing its market position.
- Industry-Wide Impact: The surge in ZIM's stock price could influence investor sentiment across the shipping industry, prompting fluctuations in the stock prices of other related companies and affecting overall industry performance.
- Increased Investor Attention: As the stock price rises, ZIM may attract more attention from analysts and investors, further driving its market performance and trading volume, thereby strengthening the company's competitiveness in the shipping market.
See More
U.S. Stocks Mostly Higher in Morning Trade, Dow Up Over 200 Points
- Dow Jones Performance: The Dow Jones index rose over 200 points on Thursday, gaining 0.45% to reach 50,348.12, reflecting optimistic market sentiment towards economic recovery, which may attract more investor interest.
- Jobless Claims Data: U.S. initial jobless claims fell by 5,000 to 227,000, below market expectations of 222,000, indicating ongoing improvement in the labor market that could boost consumer confidence.
- Real Estate Sector Recovery: Real estate stocks gained 2.1% on Thursday, reflecting increased market confidence in real estate investments, which may promote further development in related industries.
- Commodity Market Fluctuations: Oil prices fell by 0.8% to $64.09, while gold prices dipped 0.4% to $5,079.00, indicating a cautious investor sentiment in the commodities market that could impact earnings expectations for related companies.
See More
Fastly Reports Strong Quarterly Earnings Exceeding Expectations
- Strong Earnings Performance: Fastly reported earnings of $0.12 per share, surpassing analyst expectations of $0.06, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Significant Revenue Growth: The quarterly revenue reached $172.61 million, exceeding Wall Street's estimate of $161.36 million and up from $140.58 million in the same period last year, demonstrating the company's robust performance amid recovering market demand.
- Stock Price Surge: Fastly's shares jumped 34.8% to $12.55 in pre-market trading, reflecting a positive investor reaction to the earnings report, which may attract more investor interest in its future developments.
- Increased Market Confidence: The strong earnings report not only enhances investor confidence but may also prompt analysts to revise their ratings and price targets for the company, potentially driving further stock price increases.
See More
STRATA Showcases New Technologies at 2025 Dermatology Congress, Anticipates 12 New Clients in Mexico
- Technology Showcase: At the 2025 Ibero-Latin American Dermatology Congress, STRATA presented its XTRAC® laser and TheraclearX® acne therapy system, garnering significant interest from dermatologists and reinforcing the company's leadership in dermatological technologies.
- Market Expansion: STRATA anticipates over 12 new recurring TheraclearX® accounts in Mexico by the end of 2025, reflecting growing acceptance of non-drug treatment options among dermatologists in the region, which will drive sustainable revenue growth for the company.
- Clinical Feedback: At the congress, the first TheraClearX® user in Mexico shared her successful experience in treating mild to moderate acne, highlighting the technology's potential for significant patient improvement in a short session, which could enhance adoption rates.
- Strategic Outlook: STRATA is committed to expanding access to advanced dermatology solutions across Latin America, engaging with key opinion leaders to enhance market penetration and drive revenue growth through device-based therapies.
See More
